ADP-induced platelet activation

Critical Reviews in Biochemistry and Molecular Biology

Volumn 32, Issue 6, 1997, Pages 437-502

  Puri, Rajinder N ^a   Colman, Robert W ^a  

^a TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

ADP induced platelet activation mechanisms; ADP receptor; Aggregin; Drugs inhibiting ADP induced platelet aggregation; Identification and cloning; Purinergic Receptors

Indexed keywords

ADENOSINE DIPHOSPHATE; ADENOSINE TRIPHOSPHATE; ADENYLATE CYCLASE; CLOPIDOGREL; DIADENOSINE TETRAPHOSPHATE; FPL 66096; FPL 67085; PURINE RECEPTOR; TICLOPIDINE; UNCLASSIFIED DRUG;

ARTERY THROMBOSIS; CALCIUM MOBILIZATION; CORONARY ARTERY DISEASE; ENZYME INHIBITION; HEART INFARCTION; HEMOSTASIS; HUMAN; NONHUMAN; PATHOGENESIS; PHOTOAFFINITY LABELING; PRIORITY JOURNAL; REVIEW; STROKE; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOCYTE SHAPE; UNSTABLE ANGINA PECTORIS;

ANGINA;

EID: 0031415720     PISSN: 10409238     EISSN: None     Source Type: Journal    
DOI: 10.3109/10409239709082000     Document Type: Review

References (309)

1. Devary, A. N. and Szent-Gyorgi, A. 1929. The physiological activity of adenine compounds, with special reference to their action on heart. J. Physiol. 68: 213-217
2. Su, C. 1988. Purinergic neurotransmission and neuromodulation. Ann. Rev. Pharmacol. Toxicol. 23: 397-411.
3. Green, H. and Stoner, H. B. 1950. Biological Actions of Nucleotides, H. K. Lewis & Co., Ltd., London.
4. Burnstock, G. and Kennedy, C. 1986. A dual function of adenosine 5′-triphosphate in the regulation of vascular tone. Excitatory cotransmitter with noradrenaline from perivascular nerves and locally realesed intravascular agents. Circ. Res. 58: 319-330.
5. Olson, R. A. and Pearson, J. D. 1990. Cardiovascular purinoreceptors. Physiol. Rev. 70: 761-849.
6. 2-purincrgic receptors for extracellular ATP. Am. J. Respir. Cell Mol. Biol. 4: 295-300.
7. Von Kugelgen, I. and Strake, K. 1991. Noradrenaline-ATP cotransmission in symphathetic nervous system. Trends Pharmacol. Sci. 12: 319-324.
8. Bean, B. P. 1990. Pharmacology and electrophysiology of ATP-activated ion channels. Trends Pharmacol. Sci. 13: 87-91.
9. Burnstock, G. 1990. Purinergic mechanisms. Ann. N.Y. Acad. Sci. 603: 1-17.
10. El-Moatassim, C., Dornand, J., and Mani, J. C. 1992. Extracellular ATP and cell signalling. Biochim. Biophy. Acta 1134: 31-45.
11. Vassort, G., Scamps, F., Puceat, M., and Clement, O. 1992. Multiple effects of extracellular ATP in cardiac tissues. News Physiol. Sci. 7: 212-215
12. 2-purinergic receptors for extracellular ATP and other nucleotides. Am. J. Physiol. 265: C577-C606.
13. Apasov, S., Koshiba, M., Redgeld, F., and Sitrovsky, M. V. 1995. Role of extracellular ATP and P1 and P2 classes of purinergic receptors in T-cell development and cytoxic T-lymphocyte effector functions. Immunol. Rev. 146: 5-19.
14. Baricordi, R., Ferrair, D., Mechiorri, L., Chiozzi, P., Hanan, S., Chiari, E., Rubin, M., and Di Virgilio, F. 1996. An ATP-channel is involved in mitogenic stimulation of human T-lymphocyte. Blood 86: 682-690.
15. Zheng, L., Zychlinski, A., Liu, C., Ojcius, D., and Young, J. 1991. Extracellular ATP as a trigger for apoptosis or programmed cell death. J. Cell Biol.. 112: 279-285.
16. 2Z receptor: An intriguing role in immunity, inflamation and cell death. Immunol. Today 16: 524-528.
17. Hellem, A. J. 1960. The adhesiveness of human blood platelets in vitro. Scand. J. Clin. Lab. Invest. 12: 1-117.
18. Olligard, E. 1961. Macroscopic studies of platelet aggregation: nature of an aggregating factor in red blood cells and platelets. Thromb. Diath. Haemorrh. 6: 86-97.
19. Gaarder, A. Jonsen, A., Laland, S., Hellem, A. J., and Owern, P. 1961. Adenosine diphosphate in red cells as a factor of human blood platelets. Nature 192: 531-532.
20. Born, G. V. R. 1962. Aggregation of blood platelets by adenosine diphosphate and its reversal. Nature 194: 927-929.
21. Clayton, S. and Cross, M. J. 1963. The aggregation of platelets by catecholamine and by thrombin. J. Physiol. 169: 82P-83P.
22. Clayton, S., Born, G. V. R., and Cross, M. J. 1963. Inhibition of the aggregation of blood platelets by nucleosides. Nature 200: 138-139.
23. Haslam, R. J. 1964. Role of adenosine diphosphate in the aggregation of human blood platelets by thrombin and fatty acids. Nature 202: 765-68.
24. Haslam, R. J. 1967. Mechanisms of blood platelet aggregation. In Physiology of Hemostasis and Thrombosis (Johnson, S. A., and Seegers, W. H., Eds.) pp. 88-112 Charles C. Thomas, Springfield, IL.
25. Willerson, J. T., Campbell, W. B., Winniford, H. D., Schmitz, J., Apprill, P., Firth, B. G., Ashton, J., Smitherman, T., Bush, L., and Buja, L. M. 1984. Conversion from chronic to acute coronary artery disease: speculations regarding mechanisms. Am. J. Cardiol. 54: 1349-1354.
26. Willerson, J. T., Hills, L. D., Winniford, M., and Buja, L. M. 1986. Speculations regarding mechanisms responsible for acute ischemic heart disease syndromes. J. Am. Coll. Cardiol. 8: 245-250.
27. Willerson, J. T., Golino, P., Eidt, J., Campbell, W. B., and Buja, L. M. 1989. Specific platelet mediators and unstable coronary artry lesions: Experimental evidence and potential clinical implications. Circulation 80: 198-205.
28. Davis, M. J. and Thomas, A. C. 1985. Plaque fssuring: the cause of acute myocardial infarction, sudden death, and crescendo angina. Br. Heart J. 53: 363-373.
29. Fuster, V., Bradmon, L., Cohen, M., Ambrose, J. A., Bradmon, J. J., and Chesboro, J. H. 1988. Insights into pathogenisis of acute ischemic syndromes. Circulation 77: 1213-1220.
30. Davis, M. J. 1994. Mechanisms of thrombosis and atherosclerosis, in Haemostasis and Thrombosis: Basic Principles and Clinical Practice (Colman, R. W., Hirsh, J., Marder, V. J., and Salzman, E. W., Eds.) pp. 1224-1237, J. B. Lippincott Company, Philadelphia.
31. Baumgartner, H. R. 1973. The role of blood flow in platelet adhesion and, fibrin formation of murual thrombi. Microvasc. Res. 5: 167-179.
32. Baumgartner, H. R., Muggli, R., Tschopp, T. B., and Turitto, V. T. 1976. Platelet adhesion, release and aggregation in flowing blood: effect of surface properties and platelet function. Thromb. Haemost. 35: 124-138.
33. Turittio, V. T., Weiss, H. J., Zimmerman, T. S., and Susman, I. L. 1985. Factor VIII/von Willebrand factor in subendothelium mediates platelet adhesion. Blood 65: 823-831.
34. Stel, H. V., Sakariassan, K. S., De Groot, P. G., van Maurik, J. A., and Sixma, J. J. 1985. von Willebrand factor in the vessal wall mediates platelet adhesion. Blood 6: 329-357.
35. Kieffer, N. and Phillips, D. R. 1990. Platelet membrane glycoproteins: functions in cellular interactions. Ann. Rev. Cell Biol. 6: 329-357.
36. Nurden, A. T. and Nurden, P. 1993. A review of the role of platelet membrane glycoproteins in the platelet vessel wall interaction. Balliere's Clinical Hematology 6: 653-690.
37. Zawilska, K. M., Born, G. V. R., and Bengent, N. A. 1982. Effect of ADP-utilizing enzymes on arterial bleeding time in rats and rabbits. Br. J. Haematol. 50: 317-325.
38. Schror, K. 1993. The basic pharmacology of ticlopidine and clopidogrel. Platelets 4: 252-261.
39. Yao, S.-K., Ober, J. C., McNatt, J., Benedict, C. R., Rosolowski, M., Anderson, H. V., Cui, K., Maffrand, J.-P., Campbell, W. B., Buja, L. M., and Willerson, J. T. 1991. ADP plays an important role in mediating platelet aggregation and cyclic flow variations in vivo in stenosed and endothelium-injured canine coronary arteries. Circulation Res. 70: 39-48.
40. Panak, E., Maffrand, J. P., Picard-Fraire, C., Valles, E., Blanchard, J., and Rencucci, R. 1983. Ticlopidine: a promise for prevention and treatment of thrombus and its complications. Haemostasis 13 Suppl 1: 1-54.
41. Thenault, J. McEwen, J., McCrew, A. Bouloux, C., Jacob, C., Chigot, C., Irvine, A., Kindermans, M., Maffrand, J. P., and Rencucci, R. 1986. PCR 4099. A new antithrombotic drug, evaluation of tolerence and pharmacological activity. Thromb. Res. Suppl 6: 286.
42. Maffrand, J. P., Bernat, A., Delebassee, D., Defreyn, G., Cazenave, J. P., and Gorden, J. L. 1988. ADP plays a key role in thrombogenesis in rats. Thromb. Haemost. 59: 225-230.
43. Cattaneo, M., Leochi, A., Randi, A. M. N., McGregor, J. L., and Mannucci, P. M. 1992. Identification of new congenital defect of platelet function characterized by severe impairment of platelet responses to adenosine diphosphate. Blood 80: 2787-2796.
44. Nurden, P., Savi, P., Heilman, E., Bihour, C., Herbert, J-M., Maffrand, J.-P., and Nurden, A. T. 1995. An inherited bleeding disorder linked to defective interaction between ADP and its receptor on platelets. J. Clin. Invest. 95: 1612-1622.
45. George, J. N., Nurden, A. T., and Phillips, D. R. 1984. Molecular defects in intertactions of platelets with the vessel wall. N. Engl. J. Med. 311: 1084-1098.
46. Weiss, H. J. 1994. Inherited abnormalities of platelet granules and signal transduction, in Hemostasis and Thrombosis: Basic Principles and Clinical Practice (Colman, R. W., Hirsh, J., Marder, V. J., and Salzman, E. W., Eds.) pp. 1224-1237, J. B. Lippincott Company, Philadelphia.
47. 4-tetraphosphate. Proc. Natl. Acad. Sci. U.S.A. 89: 11056-11058.
48. Vilen, L., Jacobsson, S., and Kutti, J. 1989. ADP-induced platelet aggregation as a function of age in healthy humans. Thromb. Hemost. 61: 490-492.
49. Burnstock, G. 1972. Purinergic nerves. Pharmacol. Rev. 24: 509-581.
50. Kenakin, T. P., Bond, R. A., and Bonner, T. I. 1992. Definition of pharmacological Receptors. Pharmacol. Rev. 44: 351-361.
51. Burnstock, G. 1978. A basis for distinguishing two types of purinergic receptors, in Cell Membrane Receptors for Drugs and Hormones: A Multidisciplinary Approach (Sraub, R. W. and Bolis, L., Eds.) pp. 107-118, Raven Press, New York.
52. Van Calker, P., Muller, M., and Hamprecht, B. 1979. Adenosine regulates via two different types of receptors; the accumulation of cyclic AMP in cultured brain cells. J. Neurosci. 23: 999-1005.
53. Londos, C., Cooper, D. M. F., and Wolff, J. 1980. Subclasses of external adenosine receptors. Proc. Natl. Acad. Sci. U.S.A. 77: 2551-2554.
54. 1-subtype. Eur. J. Pharmac. 100: 363-368.
55. Linden, J. 1991. Structure and function of A1 adenosine receptors. FASEB J. 5: 2668-2776.
56. Barnard, E. A., Burnstock, G., and Webb, T. E. 1994. G-protein coupled receptors for ATP and other nucleotides: a new receptor family. Trends Pharmacol. Sci. 15: 67-70.
57. Burnstock, G. and Kennedy, C. 1985. Is there a basis for distinguishing purinergic receptors? Gen. Pharmac. 16: 433-440.
58. Cusack, N. J. and Hourani, S. M. O. 1990. Subtypes of P2-Purinoreceptors: Studies using analogs of ATP. Ann. N.Y. Acad. Sci. 603: 172-181.
59. Gordon, J. L. 1986. Extracellular ATP: effects, sources and fate. Biochem. J. 233: 309-319.
60. Fredholm, B. B., Abbracchio, M. P., Burnstock, G., Daly, J. W., Harden, T. K., Jacobson, K. A., Leff, P., and Williams, M. 1994. VI. Nomenclature and classification of purinoreceptors. Pharmacol. Rev. 46: 143-156.
61. 2 purinergic receptors for diadenosinepolyphosphates in the nervous system. Gen. Pharmacol. 26: 229-235.
62. 2+ permeable channel activated by ATP in the smooth muscle. Nature 328: 275-278.
63. Surprenant, A., Buell, G., and North, R. A. 1995. P2X receptors bring new structure to ligand-gated ion channels. Trends Neur. Sci. 18: 224-228.
64. Brake, A. G., Wagenbach, M. J., and Julius, D. 1994. New structural motif for ligandgated ion channels defined by ionotropic ATP receptor. Nature 371: 519-523.
65. Lambrecht, G., Friebbe, T., Grimm, U., Windsceif, U., Bungart, E., Hildebrandt, C., Beaumert, H. G., Spatz-kümbel, G., and Mutschler, E. 1992. PPADS, a novel functionally selective antagonist of P2 purinoreceptor mediated responses. Eur. J. Pharmacol. 217: 217-219.
66. 1 receptor activation in HL-60 cells. Blood 87: 2659-2664.
67. Valera, S., Hussey, N., Evans, R. J., Adami, N., Norte, R. A., Surprenant, A., and Buell, G. 1994. A new class of ligand-gated ion channel defined by P2X receptor for extracellular ATP. Nature 371: 516-519.
68. O'Connor, S. E., Dainty, I. A., and Leff, P. 1991. Further subclassification of ATP Receptors based on agonist studies. Trends Pharmacol. Sci. 12: 137-141.
69. 2-purinoreceptor activation stimulates phosphoinositide hydrolysis and inhibits accumulation of cAMP in cultured ventricular monocytes. Circulation Res. 70: 477-485.
70. Boyer, J. L., Lazarowski, I. R. Cheu, X.-H., and Harden, T. K. 1993. Identification of a P2Y-purinergic receptor that inhibits adenylyl cyclase. J. Pharmacol. Exp. Ther. 267: 1140-1146.
71. Bruner, G. and Murphy, S. 1990. ATP-evoked arachidonic acid mobilization in astrocytes is via a P2Y-Purinergic receptor. J. Neurochem. 55: 1569-1575.
72. Hoyl, C. H., Knight, G. C., and Burnstock, G. 1990. Suramin antagonizes responses to P2-purinoreceptor agonists and purinergic nerve stimulation in the guinea-pig urinary bladder and E. coli. Br. J. Pharmacol. 99: 617-621.
73. 1 receptor. Biochem. Biophys. Res. Commun. 218:783-788.
74. Parr, C. E., Sullivan, D. M., Paradiso, A. M., Lazarowski, G. R., Burch, L. H., Olsen, J. C., Erb, L., Weimann, G. A., Boucher, R. C., and Turner, J. T. 1994. Cloning and expression of a human P2U nucleotide receptor, a target for cystic fibrosis pharmacotherapy. Proc. Natl. Acad. Sci. U.S.A. 91: 3275-3279.
75. Akabar, G. K. M., Dcssari, V. P., Sheth, S., Mills, D. C. B., and Kunapuli, S. P. 1995. Identification of two calcium signalling P2T and P2U purinergic receptors in human erythroleukemia cells. FASEB J. 9: 684 (Abstract).
76. Niguyen, T., Erb, L., Weisman, G. A., Murschese, A., Heng, H. H. Q., Gurrard, R. C., George, S. P., Turner, J. T., and O'Dowd, B. F. 1995. Cloning and expression, and chromosomal localiztion of the human uridine receptor gene. J. Biol. Chem. 270: 30846-30848.
77. Communi, D., Priotton, S., Parmentier, M., and Boeynaems, J. M. 1995. Cloning and functional expression of a human uridine nucleotide receptor. J. Biol. Chem. 270: 30849-30852.
78. 5. Biochem. Biophys. Res. Commun. 219: 105-110.
79. Chang, K., Hanaoka, K., Kumada, M., and Takuwa, Y. 1995. Molecular cloning and functional analysis of a novel P2 nucleotide receptor. J. Biol. Chem. 270: 26152-26158.
80. Akbar, G. K. M., Dasari, V. R., Webb, T. E., Ayanathan, K. P., Pillarisetti, K., Sandhu, A. K., Athwal, R. S., Daniel, J. L., Ashby, B., Barnard, E. A., and Kunapuli, S. P. 1996. Molecular cloning of a novel P2 purinoreceptor from human erythroleukemia cells. J. Biol. Chem. 271: 18363-18367.
81. Hubert, M. F., Trumpp-Kallmeyer, S., Hoflock, J., and Bruinvels, A. 1993. This is not a G-protein-coupled receptor. Trends Pharmacol. Sci. 14: 7-12.
82. Cockroft, S. and Gomperts, B. D. 1979. Activation and inhibition of calcium-dependent histamine secretion by ATP ions applied to mast cells. J. Physiol. 296: 229-243.
83. 4-receptor that mediates permeabilization of rat mast cells. Eur. J. Pharmacol. 147: 13-21.
84. Erb, L., Lustig, K. D., Sullivan, D. M., Turner, J. T., and Weisman, G. A. 1993. Functional expression and photoaffinity labeling of a cloned P2U Purinergic receptor. Proc. Natl. Acad. Sci. U.S.A. 90: 5113-5117.
85. Lustig, K. D., Shian, A. K., Brake, A. J., and Julius, D. 1993. Expression cloning of an ATP receptor from mouse neuroblastoma cells. Proc. Natl. Acad. Sci. U.S.A. 90: 5113-5117.
86. Clarke, L. L., Grubb, B. R., Yankaskas, J. R., Cotton, C. U., Mekenzie, A., and Boucher, R. C. 1994. Relationship of a non-cystic fibrosis transmembrane conductance regulator-mediated chloride conductance to organ-level decreases in cftr(-l-) mice. Proc. Natl. Acad. Sci. U.S.A. 91: 479-483.
87. Bear, C. E., Li, C., Kartner, N., Bridges, R. J., Jensen, J. R., Ramjeesingh, M., and Riorden, J. R. 1992. Purification and functional reconstitution of the cystic fibrosis transmission conductance regulator. Cell 68: 809-818.
88. Mason. S. J., Paradiso, A. M., and Boucher, R. C. 1991. Regulation of trans epithelial ion transport and intracellular calcium by extracellular ATP in human normal and cystic fibrosis airway epithelium. Br. J. Pharmacol. 103: 1649-1656.
89. Knowles, M. R., Lane, L., Clarke, D. V. M., and Boucher, R. C. 1991. Activation of extracellular nucleotides of chloride secretion in the airway epithelia of patients with cystic fibrosis. N. Engl. J. Med. 325: 533-538.
90. Cusack, N. J. and Hourani, S. M. O. 1982. Adenosine-5′-diphosphate antagonists and human platelets: No evidence that aggregation and inhibition of adenylate cyclase are mediated by different Receptors. Br. J. Pharmacol. 76: 221-227.
91. Macfarlane, D. E. and Mills, D. C. B. 1975. The effects of ATP on platelets: evidence against centeral role of released ADP in primary aggregation. Blood 46: 309-320.
92. Rink, T. J. and Hallam, T. J. 1984. What turns platelets on? Trends Biochem. Sci. 9: 215-219.
93. Hallam, T. J. and Rink, T. J. 1985. Response to adenosine diphosphate in human blood platelets loaded with the flourescent calcium indicator Quin-2. J. Physiol. 368: 131-146.
94. 2+ entry regulated by the intracellular store. Biochem. J. 265: 675-680.
95. Sage, S. O. and Rink, T. 1986. Kinetic differences between thrombin- and ADP-induced calcium influx and release from internal stores in fura-2 loaded human platelets. Biochem. Biophys, Res. Commun. 136: 1124-1129.
96. Mahaut-Smith, M. P., Sage, S. O., and Rink, T. J. 1990. Rapid ADP-evoked currents in human platelets recorded with nystatin permeabilized patch technique. J. Biol. Chem. 267: 3060-3065.
97. Macfarlane, D. E. and Mills, D. C. B. 1981. Inhibition by ADP of prostaglandin-induced accumulation of cyclic AMP in human platelets. J. Cyclic Nucleotide Res. 7: 1-11.
98. Cusack, N. J. and Hourani, S. M. O. 1982. Competitive inhibition by adenosine 5′-triphosphate of the actions of human platelets by 2-chloroadenosine 5′-diphosphate, 2-azidoadenosine 5′-diphosphate and 2-methylthioadenosine 5′-diphosphate. Br. J. Pharmacol. 77: 329-333.
99. 32P]diphosphate: an agonist and radioligand for the receptor that inhibits the accumulation of cyclic AMP in platelets. J.Clin. Invest. 71: 420-428.
100. Fugman, D. A., Write, D. P., Jones, L. A. C., Aronow, B. J., and Liberman, M. A. 1990. In vitro establishment and characterization of a human megakaryoblastic cell line. Blood 75: 1252-1261.
101. Kalambakas, S. A., Robertson, F. M., O'Connell, S. M., Sinha, S., Vishnupad, K., and Karp, G. I. 1993. Adenosine diphosphate stimulation of cultured hematopoietic cell lines. Blood 81: 2652-2657.
102. Shi, X.-P., Yin, K.-C., and Gardell, S. J. 1995. Human erythroleukemic (HEL) cells express a platelet P2T-like ADP receptor. Thromb. Res. 77: 235-247.
103. 2U purinoreceptors in human megakaryoblasic Dami Cells. Blood 83: 1258-1267.
104. 4-tetraphosphate are present and releasable but metabollically inactive in human platelets. Biochem. J. 208: 737-742.
105. 3A) in human platelets. Biochem. Biophys. Res. Commun. 115: 253-260.
106. 5A-in bovine adrenal medulla: presence in chrimaffin granules. J. Neurochem. 51: 1696-1703.
107. 4A) on platelet aggregation in unfractionated human blood. Blut 51: 405-413.
108. Harrison, M. J., Brossmer, R., and Goody, R. S. 1975. Inhibition of platelet aggregation and platelet release reaction by α,ω-diadenosine polyphosphates. FEBS Lett. 54: 57-60.
109. Mayo, K. H., Mvele, O. M., and Puri, R. N. 1990. Proton magnetic resonance spectroscopic analysis of diadenosine 5,5′-polyphosphates. FEBS Lett. 265: 97-100.
110. Castro, E., Torres, M., Miras-Portugal, M. T., and Gonzalez, M. P. 1990. Effect of diadenosine polyphosphates on catecholamine secretion from isolated chromaffin cells. Br. J. Phatrmacol. 100: 360-364.
111. d 7.9 μmol/L) platelet binding sites for ADP and competition by ADP analogs. Blood 71: 100-116.
112. Puri, R. N., Kumar, A., Chen, H., Colman, R. F., and Colman, R. W. 1995. Inhibition of ADP-induced platelet responses by covalent modification of aggregin, a putative ADP-receptor, by 8-(4-bromo-2,3-dioxobutylthio)-ADP. J. Biol. Chem. 270: 24482-24488.
113. Gough, G., Maguire, M. H., and Penglis, F. 1972. Analogs of adenosine 5′-diphosphate: new platelet aggregators. Influence of purine ring and phosphate chain substituents on aggregatory of adenosine 5′-diphosphate. Mol. Pharmacol. 8: 170-177.
114. Puri, R. N., Colman, R. F., and Colman, R. W. 1996. Platelet activation by 2-(4-bromo-2,3-dioxobutylthio)adenosine 5′-diphosphate is mediated by its binding to a putative ADP-receptor, aggregin. Eur. J. Biochem. 236: 862-870.
115. Colman, R. W., Figures, W. R., Scearce, M. L., Strimpler, A. M., Zhou, F., and Rao, K. 1986. Inhibition of collagen induced platelet activation by 5′-fluorosulfonylbenzoyladenosine. Evidence for an ADP requirement and synergistic influence of prostaglandin endoperoxides. Blood 68: 565-570.
116. Pierce, P. H., Wright, J. M., Egan, C., and Scrutton, M. C. 1978. Interaction of human platelets with 2,3-dialdehyde and 2,3-dialcohol derivatives of adenosine diphosphate and adenosine triphosphate. Eur. J. Biochem. 88: 543-554.
117. Pun, R. N. and Colman, R. W. 1997. Structural features in the ribose moiety of ADP necessary for interaction with aggregin, an ADP-receptor, during ADP-induced platelet responses: investigations using apolyclonal antibody. FASEB J. 9: 329 (Abstract).
118. Cusack, N. J. and Hourani, S. M. O. 1981. Partial agonist behaviour of adenosine-5′-O-(2-thiodiphosphate). Br. J. Pharmacol. 73: 405-408.
119. p diastereoisomers of adenosine-5′-O-(1-thiodiphosphate) on human platelets. Br. J. Pharmacol. 73: 409-412.
120. Cusack, N. J. and Petty, C. J. 1988. Effects of isopolar isosteric phosphonate analogues of adenosine 5′-diphosphate (ADP) on human platelets, in Adenosine and Adenosine Nucleotides: Physiology and Pharmacology (Paton, D. M., Ed.) p. 287, Taylor and Francis, London.
121. Hourani, S. M. O., Welford, L. A., and Cusack, N. J. 1986. 2-MeS-AMP-PCP and human platelets: implications for the role of adenylate cyclase in ADP-induced aggregation? Br. J. Pharmacol. 87: 84P.
122. Cusack, N. J. and Hourani, S. M. O. 1982. Specific and non-compatative inhibition by 2-alkylthio analogues of adenosine 5′-monophosphate and adenosine 5′-triphosphate of human platelet aggregation by adenosine 5′-diphosphate. Br. J. Pharmacol. 75: 397-400.
123. Cusak, N. J., Hickmann, M. E., and Born, G. V. R. 1979. Effect of D- and L-enantiomers of adenine, AMP and ADP and their 2-chloro and 2-azido analogues on human platelets. Proc. R. Soc. London Ser B 206: 139-144.
124. Burnstock, G., Cusack, N. J., Hills, J. M., Mackenzie, A. I., and Meghiji, P. 1983. Studies on the stereoselectivity of P2-purinoreceptor. Br. J. Pharmacol. 79: 907-913.
125. Cusack, N. J. and Born, G. V. R. 1977. Effects of photolysable 2-azido analogues of AMP and ADP on human platelets. Proc. R. Soc. London Ser B 197: 515-520.
126. Cristalli, G. and Mills, D. C. B. 1993. Identification of a receptor for ADP on blood platelets by photoaffinity labeling. Biochem. J. 291: 875-881.
127. Jefferson, J. R., Hunt, J. B., and Jamieson, G. A. 1987. Facile synthesis of 2-[(3-aminopropyl)thio]adenosine 5′-diphosphate: a key intermediate for the synthesis of molecular probes of adenosine 5′-diphosphate function. J. Med. Chem. 30: 2013-2016.
128. Puri, R. N. and Colman, R. W. 1997. Modulation of platelet responses by 2-(3-bromo-2-oxopropylthio)adenosine 5′-diphosphate involves its binding to as well as covalent modification of an ADP-receptor, aggregin. Arch. Biochem. Biophys. 343: 140-145.
129. Cusack, N. J. and Born, G. V. R. 1976. Inhibition of adenosine deaminase and of platelet aggregation by 2-azidoadenosine, a photolysable analogue of adenosine. Proc. R. Soc. London Ser. B 197: 307-311.
130. 32P]diphosphate to the receptor on intact human blood platelets which inhibits adenylate cyclase. Biochemistry 21: 544-549.
131. Bennett, J. E., Colman, R. F., and Colman, R. W. 1978. Identification of adenine nucleotide proteins in human platelet membranes by affinity labeling by 5-p′-fluorosulfonylbenzoyladenosine. J. Biol. Chem. 253: 7346-7354.
132. Colman, R. F. 1990. Site specific modification of enzyme sites, in Enzymes, Vol. 19, pp. 283-321, Academic Press, New York.
133. Agarwal, A. K., Tandon, N. N., Greco, N. J., and Jamieson, G. A. 1989. Evaluation of the binding to fixed platelets of agonists and antagonists of ADP-induced platelet aggregation. Thromb. Haemost. 62: 1103-1106.
134. Greco, N. J., Yamamoto, N., Jackson, B. W., Tandon, N. N., Moos, M., Jr., and Jamieson, G. A. 1991. Identification of a nucleotidebinding site on glycoprotein IIb. J. Biol. Chem. 266: 13627-13636.
135. 2+ influx into stimulated platelets. Blood 66: 731-734.
136. Greco, N. J., Tandon, N. N. Jackson, B. W., and Jamieson, G. A. 1992. Low structural specificity for nucleoside triphosphates as antagonists of ADP-induced platelet activation. J. Biol. Chem. 267: 2966-2970.
137. 3 (glycoprotein IIb-IIIa) on intact platelets with 8-azido-[γ-32P]ATP. Biochim. Biophys. Acta 1137: 77-81.
138. Guthrow, C. E., Allen, J. E., and Rasmussen, H. 1972. Phosphorylation of an endogenous membrane associated cyclic adenosine 3′,5′-diphosphate dependent protein kinase in human erythrocyte ghosts. J. Biol. Chem. 247: 8145-8153.
139. Antonoff, R. S. and Ferguson, J. J., Jr. 1974. Photoaffinity labeling with cyclic nucleotidcs. J. Biol. Chem. 249: 3319-3321.
140. Obrig, T. G., Antonoff, R. S., Kirwin, K. S., and Ferguson, J. J., Jr. 1975. The binding of adenosine-3′,5′-monophosphate by messenger ribonucleotide-like particles. Biochem. Biophys. Res. Commun. 66: 437-443.
141. Schimmel, P. R. and Budzik, G. P. 1977. Photo-cross-linking of protein-nucleic acid complexes. Methods Enzymol. 46: 168-180.
142. Wang, S. Y., Ed. 1974. Photochemistry and Photobiology of Nucleotides, Gordon & Beach, New York.
143. Oswald, R. and Changeux, J.-P. 1991. Ultraviolet light-induced labeling by non-competitive blockers of acetylcholine receptor from torpedo marmorata. Proc. Natl. Acad. Sci U.S.A. 78: 3925-3929.
144. Van Prooijen, H. C., Van Marwizk-Kooy, M., Van Weelden, H., Aarts-Riemens, M. I., Borghuis, L., and Akkerman, J. W. N. 1990. Evidence of a new UVB source for irradiation of platelet concentrates. Br. J. Haemotol 75: 573-577.
145. Van Marwizk-Kooy, Van Prooijen, H. C., Van Asbeck, B. S., Borghuis, L., and Akkerman, J. W. N. 1990. Irradation of platelets with UV-B light exposes fibrinogen binding sites by an intracellualr mechanism. Br. J. Haematol. 75: 573-577.
146. Van Marwizk-Kooy, M., Akkerman, J. W. N., Van Asbeck, B. S., Borghuis, L., and Van Prooijen, H. C. 1990. UVB radiation exposes fibrinogen binding sites on platelets by activating protein kinase C via reactive oxygen species. Br. J. Haematol. 83: 253-258.
147. Grijzenhout, M. A., Aarts-Riemens, M. I., Akkerman, J. W. N., Nienwenhuis, H. K., Van Weelden, H., and Van Prooijen, H. C. 1993. Ultraviolet-B irradiation of platelets induces a dose-dependent increase in the expression of platelet activation markers with storage. Br. J. Haematol. 83: 627-632.
148. Schieven, G. L., Kirihara, J. M., Gilliland, L. K., Uckum, F. M., and Ledbetter, J. A. 1993. Ultraviolet radiation rapidly induces tyrosine phosphorylation and calcium signalling in lymphocytes. Mol. Biol. Cell 4: 523-530.
149. Devary, Y., Gottlieb, R. A., Smeal, T., and Karin, M. 1992. The ultraviolet response is triggered by activation of src tyrosine kinases. Cell 71: 1081-1091.
150. Kyriakis, J. M., Banerjee, P., Nikolakaki, E., Dai, T., Rubie, E. A., Ahmad, M. F., Avruch, J., and Woodgett, J. R. 1994. The stress activated protein kinase subfamily of c-Jun kinases. Nature 369: 156-160.
151. Pombo, C. M., Boventre, J. V., Avruch, J., Woodgett, J. R., Kyriakis, J. M., and Force, T. 1994. The stress activated protein kinases are major c-Jun amino-terminal kinases activated by ischemia and reperfusion. J. Biol. Chem. 269: 26546-26551.
152. Herrlich, P. 1984. The mammalian genetic stress response. Adv. Enzyme Regul. 25: 485-504.
153. Roni, Z. A., Lambert, E., and Weinstein, J. B. 1990. Inducible cellular responses to ultraviolet light irradiation and other mediators of DNA damage in mammalian cells. Cell Biol. Toxicol. 6: 105-126.
154. Colman, R. F. 1989. Protein Structure and Function: A Practical Approach (Creighton, T. A., Ed.) pp. 77-99, IRL Press, New York.
155. Figures, W. R., Niewiarowski, S., Morinelli, T. A., Colman, R. F., and Colman, R. W. 1981. Affinity labeling of human platelet membrane protein with 5′-p-fluorosulfonylbenzoyladenosine. J. Biol. Chem. 256: 7789-7795.
156. Figures, W. R., Scearce, M. L., DeFeo, P., Stewart, G., Zhou, F., Chen, J., Daniel, J. L., Colman, R. F., and Colman, R. W. 1987. Direct evidence for the interaction of the nucleotide affinity analog 5′-p-fluorosulfonylbenzoyladenosine with a platelet ADP receptor. Blood 70: 796-803.
157. Colman, R. W. 1990. Aggregin: a platelet ADP-receptor that mediates aggregation. FASEB J. 3: 1425-1435.
158. Colman, R. W. 1992. Platelet ADP Receptors stimulating shape change and inhibiting adenylate cyclase. News Physiol. Sci. 7: 274-278.
159. Mills, D. C. B., Figures, W. R., Scearce, M. L., Stewart, G. J., Colman, R. F., and Colman, R. W. 1985. Two mechanisms for inhibition of ADP-induced platelet shape change by 5′-p-fluorosulfonylbenzoyladenosine and covalent modification at an ADP binding site distinct from that inhibits adenylate cyclase. J. Biol. Chem. 260: 8078-8083.
160. Rao, A. K. and Kowalska, M. A. 1987. ADP-induced platelet shape change and mobilization of cytoplasmic ionized calcium are mediated by distinct binding sites on platelets: 5′-p-fluorosulfonylbenzoyladenosine is a weak platelet agonist. Blood 70: 751-756.
161. Morinelli, T. A., Niewiarowski, S., Kornecki, E., Figures, W. R., Wachtfogel, Y., and Colman, R. W. 1983. Platelet aggregation and exposure of fibrinogen receptors by prostaglandin endoperoxide analogs. Blood 61: 41-49.
162. 2-adrenoreceptor interaction: evidence of ADP-requirement for epinepherine-induced platelet activation and an influence of epinepherine on ADP-binding. J. Biol. Chem. 261: 5981-5986.
163. Puri, R. N., Zhou, F., Bradford, H., Hu, C.-J., Colman, R. F., and Colman, R. W. 1989. Thrombin-induced platelet aggregation involves an indirect cleavage of aggregin by calpain. Arch. Biochem. Biophys. 271: 346-358.
164. Puri, R. N., Zhou, F., Colman, R. F., and Colman, R. W. 1990. Plasmin-induced platelet aggregation is accompanied by cleavage of aggregin and indirectly mediated by calpain. Am. J. Physiol. 259: C862-C868.
165. Patthy, L. and Smith, E. L. 1975. Identification of functional arginine residues in ribonuclease A and lysozyme. J. Biol. Chem. 250: 565-569.
166. DeCamp, D. L., Lim, S., and Colman, R. F. 1988. Reaction of pyruvate kinase with the new nucleotide affinity label 8-(4-bromo-2,3-dioxobutylthio)adenosine 5′-diphosphate and 5′-triphosphate. J. Biol. Chem. 27: 7651-7658.
167. Ozturk, D. H., Safer, D., and Colman, R. F. 1990. Affinity labeling of bovine liver glutamate dehydrogenase with 8-[(4-bromo-2,3-dioxobutyl)thio]adenosine 5′-diphosphate and 5′-triphosphate. Biochemistry 29: 7112-7118.
168. Puri, R. N. and Colman, R. W. 1991. Inhibition of ADP-induced platelet shape change and aggregation by o-phthalaldehyde: evidence of covalent modification of cysteine and lysine residues. Arch. Biochem. Biophys. 286: 419-427.
169. +-dependent isocitrate dehydrogenase. J. Biol. Chem. 264: 12208-122214.
170. Huang, Y.-C. and Colman, R. F. 1984. Affinity labeleing of the allosteric ADP activation site of NAD-dependent isocitrate dehydrogenase by 6-(4-bromo-2,3-dioxobutylthio)adenosine 5′-diphosphate. J. Biol. Chem. 259: 12481-124888.
171. Bhatnagar, D., Roskoski, R., Jr., Rosendahl, M. S., and Leonard, N. Adenosine cyclic 3′,5′-diphosphate dependent protein kinase: a new fluorescence displacement technique for characterizing the nucleotide binding site on the catalytic subunit. Biochemistry 22: 6310-6317.
172. Colman, R. W., Figures, W. R., Wu, Q. X., Chung, X. Y., Morenelli, T. A., Tuszynski, G. P., Colman, R. F., and Niewiarowski, S. 1988. Distinction between glycoprotein IIIa and a 100 kDa protein (aggregin) mediating ADP-induced
173. Zablocki, J. A., Katzenellenbogen, J. A., Carlson, K. E., Norman, M. J., and Katzenellenbogen, B. S. 1987. Estrogenic affinity labels: synthesis, irreversible receptor binding, and bioacti vity of aziridine-substituted hexestrols derivatives. J. Med. Chem. 10: 829-838.
174. Wrzeszczynski, K. O. and Colman, R. F. 1994. Activation of bovine liver glutamate dehydrogenase by covalent reaction of adenosine 5′-O-[S-(4-bromo-2,3-dioxobutyl)thiophosphate] with arginine-459 in an ADP-regulatory site. Biochemistry 33: 11544-11553.
175. Bacon, C. R., Bender, R. A., and Colman, R. F. 1981. The reaction of 4-iodoactamidosalicylic acid with TPN-dependent isocitrate dehydrogenase from pig heart. J. Biol. Chem. 236: 6593-6599.
176. Puri, R. N., Bhatnagar, D., and Roskoski, R., Jr. 1985. Adenosine cyclic 3′,5′-monophosphate dependent protein kinase: fluorescent affinity labeling of the catalytic subunit from bovine skeltal muscle with o-phthalaldehyde. Biochemistry 24: 6499-6508.
177. Puri, R. N., Bhatnagar, D., Glass, D. B., and Roskoski, R., Jr. 1985. Inactivation of guanosine cyclic 3′,5′-monophosphate dependent protein kinase from bovine lung by o-phthalaldehyde. Biochemistry 24: 6508-6514.
178. Maclntyre, D. E., Grainge, C. A., Drummond, A. H., and Gordon, J. L. 1977. Effect of thiol reagents on platelet transport processes and responses to stimuli. Biochem. Pharmacol. 26: 319-323.
179. 2+ influx induced by collagen or arachidonate in rabbit platelets. Biochim. Biophys. Acta 928: 266-271.
180. Subarao, K., Kakkar, V. V., and Ganguli, P. 1978. Binding of pyridoxal phosphate to human platelets: its effect on platelet function. Thromb. Res. 13: 1017-1029.
181. Ghosh, P. B. and Whitehouse, M. W. 1968. 7-chloro-4-nitro-benzo-2-oxa-1,3-diazole: a new fluorogenic reagent for amino acids and other amines. Biochem. J. 108: 155-156.
182. Hartle, F. T. and Roskoski, R., Jr., 1982. Adenosine cyclic 3′,5′-monophosphate protein kinase from bivine brain: Inactivation of the catalytic subunit and holoenzyme by 7-chloro-4-nitro-2,1,3-benzoxadiazole. Biochemistry 21: 5175-5183.
183. Marquardt, D. and Center, M. S. 1991. Involvement of vascular adenosine triphosphate activity in multidrug resistance in HL-60 cells. J. Natl. Cancer Inst. 83: 1098-1102.
184. Puri, R. N. and Colman, R. W. 1996. Inhibition of ADP-induced platelet activation by 7-chloro-4-nitro-benz-2-oxa-1,3-diazole by covalent modification of aggregin, a putative ADP-receptor. J. Cell. Biochem. 61: 97-108.
185. Puri, R. N. and Colman, R. W. 1996. A novel method for chemical modification of functional groups other than a carboxyl group in proteins by N-ethyl-5-phenylisooxazolium-3′-sulfonate (Woodward's Reagent-K): inhibition of ADP-induced platelet responses involves covalent modification of aggregin, an ADP receptor. Anal. BIochem. 240: 251-260.
186. 2+)-ATPase from Acholeplasma laidlawii B: studies of reactive amino acid residues using group specific reagents. Arch. Biochem. Biophys. 247: 201-210.
187. Jennings, M. L. and Anderson, M. P. 1987. Chemical modification and labeling of glutamate residues at the stilbenedisulfonate site of human red blood cell band 3 protein. J. Biol. Chem. 262: 11435-11445.
188. Johnson, A. R. and Dekker, E. E. 1996. Woodward's Reagent K inactivation of Escerichia coli L-thronine dehydrogenase: Increases absorbance at 340-350 nm is due the modification of cysteine and histidine residues, not aspartate or glutamate carboxyl groups. Protein Science 5: 382-390.
189. Anestario, M., Jr., Harrison, M. L., and Gaehlen, R. L. 1990. Immunochemical detection of adenine nucleotide binding proteins to 5′-p-fluorosulfonylbenzoyladenosine. Anal. Biochem. 190: 60-65.
190. Puri, R. N. and Colman, R. W. 1997. Immunoaffinity method to identify aggregin, an ADP receptor in human blood platelets. Arch. Biochem. Biophys., 347: 263-270.
191. Adler, J. R. and Handin, R. I. 1979. Solubilization and characterization of a platelet membrane ADP-binding protein. J. Biol. Chem. 254: 1866-1872.
192. Nachman, R. L. and Ferris, B. 1974. Binding of adenosine diphosphate by isolated membranes from human platelets. J. Biol. Chem. 249: 704-710.
193. Gachet, C., Cattaneo, M. Ohlman, P., Hechler, B., Lecchi, A., Chevalier, J., Cassel, D., Mannuchi, P. M., and Cazenave, J.-P. 1995. Purinoreceptors on blood platelets: further pharmacological and clinical evidence to suggest the presence of two ADP receptors. Br. J. Haematol. 91: 434-444.
194. 3H]-2-methylthio-ADP to rat platelets-effect of clopidogrel and ticlopidine. J. Pharm. Exp. Therp. 269: 772-777.
195. Savi, P., Laplace, M. cI., and Herbert, J. M. 1994. Evidence for the existance of two different ADP-binding sites on rat platelets. Thromb. Res. 76: 157-169.
196. Mills, D. C. B., Puri, R. N., Hu, C.-J., Minniti, C., Grana, G., Freedman, M. D., Colman, R. F., and Coalman, R. W. 1992. Clopidogrel inhibits binding of ADP analogues to the receptor mediating platelet adenylate cyclase. Arterio. Thromb. 12: 431-436.
197. Soslau, G. and Parker, J. 1989. Modulation of platelet function by extracellular adenosine triphosphate. Blood 74: 984-993.
198. Soslau, G., Brosky, I., and Parker, J. 1993. Occupancy of P2 purinoreceptors with unique properties modulates the function of human platelets. Biochim. Biophys. Acta 1177: 199-207.
199. White, J. G., Rao, G. H. R., and Gerrad, J. M. 1974. Effects of ionophore A23187 on blood platelets. Am. J. Pathol. 77: 135-149.
200. Berridge, M. J. and Irvine, R. F. 1989. Inositol phosphates in cell signalling. Nature 341: 197-205.
201. Fisher, G. J., Bakshian, S., and Baldssare, J. J. 1985. Activation of human platelets with ADP causes a rapid rise in cytosolic free calcium without hydrolysis of phosphatidyl-4,5-bisphosphate. Biochem. Biophys. Res. Commun. 129: 958-964.
202. + exchange block epinephrine- and ADP-induced stimulation of human phospholipase C by blockade of arachidonic acid release at a prior step. J. Biol. Chem. 261: 8660-8666.
203. Vickers, J. D., Kinlough-Rathbone, R. L., and Mustard, J. F. 1986. The decrease in phosphatidyl-4,5-bisphosphate in ADP-stimulated washed rabbit platelets is not primarily due to phospholipase C activation. Biochem. J. 237: 327-332.
204. 4 incorporation into phophatidic acid and phosphoinositides of rabbit platelets. Br. J. Haematol. 24: 589-604.
205. Vickers, J. D., Kinlough-Rathbone, R. L., and Mustard, J. F. 1982. Change in phosphatidyl-4,5-bisphosphate 10 seconds after stimulation of washed platelets with ADP. Blood 60: 1247-1250.
206. Feliste, R., Simon, M. F., Chap, H., Douste-Blazy, L., Defreyn, G., and Maffrand, J. P. 1988. Effect of PCR 4099 on ADP-induced calcium movements and phosphatidic acid in rat platelets. Biochem. Pharmacol. 37: 2559-2564.
207. 3 formation in human platelets. FEBS Lett. 206: 299-303.
208. Vickers J. D., Kinlough-Rathbone, R. L., Packham, M. A., and Mustard, J. F. 1990. Inositol phospholipid metabolism in human blood platelets stimulated by ADP. Eur. J. Biochem. 193: 521-528.
209. Gear, A. R. L. and Raha, S. 1993. Calcium signalling and phosphoinosidite metabolism in platelets: subsecond events revealed by quenched flow techniques, In Mechanisms of Platelet Activation and Control (Authi, K. S., Ed.) pp. 57-67, Plenum Press, New York.
210. Jones, G. D. and Gear, A. R. L. 1988. Subsecond calcium dynamics in ADP- and thrombin-stimulated platelets: a continuous-flow approach using Indo-1. Blood 71: 1539-1543.
211. Kroll, M. K., Hellums, J. D., McIntyre, L. V., Schafer, A. I., and Moake, J. L. 1996. Platelets and shear stress. Blood 88: 1625-1541.
212. Eudo, M. 1977. Calcium release from sarcoplasmic reticulum. Physiol. Rev. 57: 71-108.
213. 2+ release from sea urchin egg homogenates: modulation by cyclic ADP-ribose. Science 253: 1143-1146.
214. 2+ release and its modulation by cyclic ADP-ribose. Trends Pharmacol. Sci. 13: 304-306.
215. Berridge, M. J. 1991. Cytoplasmic calcium oscillations. A two pool model. Cell Calcium 12: 63-72.
216. Tsenoda, Y., Matsuno, K., and Tashiso, Y. 1988. Spatial distribution and temporal change of cytoplasmic calcium in human platelets. Biochem. Biophys. Res. Commun. 156: 1152-1159.
217. Heemskerk, J. W. M., Hoyland, J., Mason, W. T., and Sage, S. O. 1992. Spiking in cytosolic calcium concentrations in single fibrinogen bound Fura 2 loaded platelet. Biochem. J. 283: 379-383.
218. 2+ homeostasis and intracellular pools in human platelets, in Mechanisms of Platelet Activation and Control (Authi, K. S., Ed.) pp. 83-104, Plenum Press, New York.
219. 2+, sn-1,2-diacylglycerol and inositol-1,4,5-triphosphate in platelet-activating factor stimulated rabbit platelets. Biochem. J. 278: 255-261.
220. Putney, J. W., Jr. 1986. A model for receptor regulated calcium entry. Cell Calcium 7: 1-12.
221. Putney, J. W., Jr. 1990.Capacitativecalcium entry revisited. Cell Calcium 11: 611-624.
222. 2+ pools and relavence in platelet activation. Biochem. J. 294: 119-226.
223. 2+ stores. Biochem. J. 280: 783-789.
224. 2+ influx. Biochem. J. 274: 193-197.
225. 2+ entry. Cell Calcium 13: 553-564.
226. Kuno, M. and Gardner, P. 1989. Ion channels activated by inositol-1,4,5-triphosphate in plasma membrane of human T-lymphocytes. Nature 326: 301-304.
227. 2+ entry by inositol phosphates - a possible mechanism. FEBS Lett. 263: 5-9.
228. 2+ release from platelet plasma membrane vesicles. Biochem. Biophys. Res. Commun. 150: 1021-1026.
229. Klan, A. A., Steiner, J. P., and Snyder, S. H. 1992. Plasma membrane inositol-1,4,5-triphosphate receptor of lymphocytes; Selective enrichment of sialic acid and unique binding specificity. Proc. Natl. Acad. Sci. U.S.A. 89: 2849-2853.
230. Fujimoto, T., Nakada, S., Miyawake, A., Mikoshiba, K., and Ogawa, K. 1992. Localization of inositol-1,4,5-triphosphate receptor-like protein plasmalemmal caveolae. J. Cell Biol. 119: 1507-1513.
231. 2+. Biochem. J. 258: 923-926.
232. Mahaut-Smith, M. P., Sage, S. O., and Rink, T. J. 1990. Receptor activated single channels in intact human platelets. J. Biol. Chem. 265: 10479-10483.
233. 2+ transport: a comparison of results obtained with platelets and human erythroleukemia cells. Blood 78: 2887-2893.
234. 2+ influx mediated through the GPIIb/ IIIa complex during platelet activation. FEBS Lett. 225: 228-232.
235. Fujimoto, T., Fujimura, K., and Kuramoto, A. 1991. Electrophysiological evidence that glycoprotein IIb-IIIa complex is involved in calcium channel activation on human platlete plasma membrane. J. Biol. Chem. 266: 16370-16375.
236. Home, W. C. and Simons, E. R. 1978. Effects of amiloride on the response of human platelets to bovine α-thrombin. Thromb. Res. 13: 599-603.
237. + eliminates indomethacin-sensitive secretion from human platelets stimulated by epinephrine, ADP, and thrombion. Proc. Natl. Acad. Sci. U.S.A. 80: 5320-5324.
238. + exchange block stimulus provoked arachidonic acid release in human platelets. J. Biol. Chem. 260: 12910-12919.
239. Siffert, W., Gengenbach, S., and Sheid, P. 1986. Inhibition of platelet aggregation by amiloride. Thromb. Res. 44: 235-240
240. Zavoico, G. B., Cragoe, E. J., and Feinstein, M. B. 1986. Regulation of intracellular pH in human platelets. J. Biol. Chem. 261: 13160-13167.
241. + exchange as a modulator of platelet activation. Trends Biochem. Sci. 13: 148-151.
242. Feinberg, H., Sandier, W. C., Scorer, M., LeBreton, G. C., Grossman, B., and Born, G. V. R. 1977. Movement of sodium into human platelets induced by ADP. Biochim. Biophys. Acta 470: 317-324.
243. 2 activation in human platelets. J. Biol. Chem. 261: 8667-8673.
244. 2 from human platelets. Biochem. Biophys. Res. Commun. 91: 63-71.
245. 2 on phosphatidylcholine modified by alkanols. J. Biol. Chem. 253: 7005-7010.
246. 2+ mobilization in human platelets stimulated by ADP and the thromboxane mimetic U46619. J. Biol. Chem. 264: 719-725.
247. Sage, S. O., Rink, T. J., and Mahout-Smith, M. 1991. Resting and ADP-evoked changes in cytosolic free sodium concentration in human platelets loaded with indicator SBFI. J. Physoiol. 44: 559-573.
248. De Cristofaro, R., Landolfi, R., De Candia, E., Castagnola, M., Di Cera, E., and Wyman, J. 1988. Allosteric equilibria in the binding of fibrinogen to platelets. Proc. Natl. Acad. Sci. U.S.A. 85: 8473-8476.
249. De Cera, E., Gill, S. J., and Wyman, J. 1988. Canonical formulation of linkage thermodynamics. Proc. Natl. Acad. Sci. U.S.A. 85: 5077-5081.
250. + exchange. Biochem. Biophys. Res. Commun. 161: 1282-1232.
251. Ross, R. 1986. The pathogenesis of atherosclerosis-An update. N. Engl. J. Med. 314: 488-500.
252. Border, W. A. and Russiatiti, L. R. 1992. Transforming growth factor-β in diseases. The dark side of tissue repair. J. Clin. Invest. 90: 1-7.
253. Amento, E. P., Ehsami, N., Palmer, H., and Libby, P. 1991. Cytokines and growth factors positively and negatively regulate interstitial collagen gene expression in human vascular smooth muscle cells. Arterioscler. Thromb. 11: 1223-1230.
254. Schwartz, L., Bourassa, M. G., Lesperance, J., Aldridge, H. E., Kazim, F., Savatore, E. A., Henderson, M., Bonem, E., and Kabid, P. R. 1988. Aspirin and dipyridamole in prevention of restonosis after percutaneous transluminal angioplasty. N. Engl. J. Med. 318: 1714-1719.
255. Thornton, M. A., Gruentzig, A. R., Hollman, J., King, S. B., III, and Douglas, J. S. 1984. Coumadin and aspirin in prevention of recurrence after transluminal coronary angioplasty. 1984. Circulation 69: 721-727.
256. Brockman, M. J., Eiroa, A. M., and Marcus, A. J. 1991. Inhibition of human platelet reactivity by endothelium-derived relaxing factor from human umbilical vein endothelial cells in suspension. Blockade of aggregation and secretion by aspirin-insensitive mechanism. Blood 78: 1033-1040.
257. Marcus, A. J., Safier, L. B., Hajjar, K. A., Ullman, H. L., Islam, N., Brookman, M. J., and Eiroa, A. M. 1991. Inhibition of platelet activation by aspirin-insensitive endothelial cell ADPase: thromboregulation of endothelial cells. J. Clin. Invest. 88: 1690-1696.
258. Rao, A. K. 1990. Congenital disorders of platelet function. Hematol. Oncol. Clin. North Am. 4: 65-86.
259. Weiss, H. J. 1994. Inherited abnormalities of platelet granules and signal transduction, in Hemostasis and Thrombosis: Basic Principles and Clinical Practice (Colman, R. W., Hirsh, J., Marder, V. J., and Saltzman, E. W., Eds.), pp. 673-684, Lippincott, Philadelphia, PA.
260. Rinder, C. S., Student, L. A., Bonan, J. L., Rinder, H. M., and Smith, B. R. 1993. Aspirin does not inhibit adenosine diphosphate-induced platelet α-granule release. Blood 82: 505-512.
261. Dillingham, E. O., Lasslo, A., Cater-Burks, G., Bond, S. E., and Gollamundi, R. 1989. Relationship between chemical structure and inhibition of ADP-stimulated human thrombocyte release of serotonin and platelet factor-4. Biochim. Biophys. Acta 990: 128-132.
262. Bell, R. L., Kennerly, D. A., Stanford, N., and Majerus, P. W. 1979. Diglyceride lipase: a pathway for arachidonate release from human platelets. Proc. Natl. Acad. Sci. U.S.A. 76: 3228-3241.
263. 2 activity specific for phosphatidic acid. A possible mechanism for the production of arachidonic acid in platelets. J. Biol Chem. 256: 831-837.
264. Packham, M. A., Livine, A.-A., Ruben, D. H., and Rand, M. L. 1993. Activation of phospholipase C has little involvement in ADP-induced primary aggregation of human platelets: effects of diacylglycerols, diacylglycerol kinase inhibitor R59022, staurosporine and okodaic acid. Biochem. J. 290: 849-856.
265. Pulcinelli, F. M., Ashby, B., Gazzauiiga, P. P., and Daniel, J. L. 1995. Protein kinase C activation is not a key step in ADP-mediated exposure of fibrinogen receptors on human platelets. FEBS Lett. 364: 87-90.
266. Friesen, L. L. and Gerrard, J. M. 1985. The effects of 1-oleoyl-2-acetylglycerol on platelet phosphorylation and platelet ultrastructure. Am. J. Pathol. 121: 79-87.
267. Gerrard, J. M., Israelis, S. J., and Friesen, L. L. 1983. Protein phosphorylation and platelet secretion. Nouv. Fr. Haematol. 27: 267-273.
268. Kaibuchi, K., Takai, Y., Sawamura, M., Hosijima, M., Fujikara, T., and Nishizuka, Y. 1983. Synergistic functions of protein phosphorylation and calcium mobilization in platelets. J. Biol. Chem. 258: 6701-6704.
269. Takai, Y., Kishimoto, A., Kikkawa, U., and Nishizuka, Y. 1979. Unsaturated diacylglycerol as a possible messenger for the calcium-activated, phospholipid dependent protein kinase system. Biochem. Biophys. Res. Commun. 91: 1218-1224.
270. Kishimoto, A., Takai, Y., Mon, T., Kikkawa, U., and Nishizuka, Y. 1980. Activation of calcium and phospholipid dependent protein kinase by diacylglycerol, its possible relation to phosphatidylinositol turnover. J. Biol. Chem. 255: 2273-2276.
271. Gerrard, J. M., Beattie, L. L., Park, J., Israels, S. J., McNicol, A., Lint, D., and Cragoe, E. J., Jr. 1989. A role of protein kinase C in membrane fusion necessary for platelet granule secretion. Blood 74: 2405-2413.
272. Gilman, A. G. 1987. G-proteins: transducers of receptor generated signals. Ann. Rev. Biochem. 56: 615-649.
273. Raymond, J. R. 1995. Multiple mechanisms of receptor-G protein signalling specificity. Am. J. Physiol. 38: F141-F158.
274. Brass, L. F., Hoxie, J. A., and Manning, D. R. 1993. Signalling through G proteins and G protein-coupled receptors during platelet activation. Thromb. Haemost. 70: 217-223.
275. Gachet, C., Cazenavc, J.-P., Ohlman, P., Gerhard, H., Wieland, T., and Jacob, K. H. 1992. ADP-receptor-induced activation of guanine-nucleotide-binding proteins in human platelet membranes. Eur. J. Biochem. 207: 259-263.
276. Laugwitz, K.-L., Spicher, K., Scultz, G., and Offermanns, S. 1994. Identification of receptor-activated G-proteins: selective immunoprecipitation of photolabeled G-protein α-subunit. Methods Enzymol. 237: 283-294.
277. i2 proteins. Biochem. J. 312: 775-779.
278. 1. Biochem. Pharmacol. 40: 2683-2687.
279. Clapham, D. E. and Neer, E. J. 1993. New roles for G-protein βγ-dimers in transmembrane signalling. Nature 365: 403-406.
280. 1 purinoreceptor. Gene 171: 295-297.
281. 1 receptor is an ADP receptor antagonized by ATP and expressed in platelets and megakaryoblastic cells. FEBS Lett. 403: 26-30.
282. Mills, D. C. B. 1996. ADP Receptors on platelets. Thromb. Haemost. 76: 835-56.
283. 1 receptor. Biochem. Biophys. Res. Commun. 221: 588-591.
284. 1-purinoreceptor. Br. J. Pharmacol. 118: 167-173.
285. Defreyn, G., Bernat, A., Delebasse, D., and Maffrand, J.-P. 1989. Pharmacology of toiclopidine: a review. Semin. Thromb. Hemost. 15: 159-166.
286. Saltiel, E. and Ward, A. 1987. Ticlopidine: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficay in platelet-dependent disease states. Drugs 34: 22-262.
287. McTavish, D., Faulds, D., and Gao, K. L. 1990. Ticlopidine. An updated review of its pharmacology and therapeutic use in platelet-dependent disorders. Drugs 40: 238-259.
288. Bruno, J. J. 1983. The mechanism of action of ticlopidine. Thromb. Res. Suppl IV: 59-67.
289. Maffrand, J.-P., Defreyn, G., Bernat, A., Delebasee, D., and Tissmier. 1988. Reviewed pharmacology of ticlopidine. Angiolgie 7: 6-13.
290. Herbert J, M., Frechel, D., Valleé, E., Kiefer, G., Gouy, D., Berger, Y., Defreyn, G., and Maffrand, J.-P. 1993. Clopidogrel, a novel antiplatelet and antithrombotic agent. Cardiovasc. Drug Rev. 11: 180-198.
291. Savi, P., Combalbert, J., Gaich, C., Rouchon, M.-C., Maffrand, J.-P., and Berger, Y. 1994. The antiaggregating activity of clopidogrel is due to a metabolic activation by the hepatic cytochrome P450-1A. Thromb. Haemost. 72: 313-317.
292. Cattaneo, M., Lombardi, R., Bettega, D., Leechi, A., and Mannuchi, M. 1993. Shear-induced platelet aggregation is potentiated by desmopressin and inhibited by ticlopidine. Arterioscl. Thromb. 13: 393-397.
293. Herbert, J.-M., Bernat, A., and Maffrand, J.-P. 1993. Aprotonin reduces clopidogrel-induced prolongation bleeding time in rats. Throm. Res. 71: 433-441.
294. Nagakawa, Y., Akedo, Y., Orimo, H., and Yano, H. 1990. Effect of combination of antiplatelet agents in man. Combination of aspirin, trapidil, ticlopidine and dipyridamole. Thromb. Res. 60: 469-475.
295. Savi, P., Bernat, A., Dumas, A., Ait-Chek, L., and Herbert, J.-M. 1994. Effects of aspirin and clopidogrel on platelet dependent tissue factor expression in endothelial cells. Thromb. Res. 73: 117-124.
296. Steiger, H., Hess, H., Mietaschek, A., Trampish, H.-J., and Ingrish, H. 1984. Einfluss von ticlopidine auf die periphere obliterierendie Arteriopathie. Dtsch. Med. Wschr. 109: 1240-1249.
297. Levy, R. I., Brensike, J. F., Epstein, S. E., Kelsey, S. F., Passamanti, E. R., Richardsson, J. M, Loh, I. K., Stone, N. J., Aldrich, R. F., Battaglini, J. W., Moriarty, D. J., Fisher, M. L., Friedman, L., Friedwald, W., and Detere, K. M. 1984. The influence of changes in lipid values induced by cholestyramine and diet on progression of coronary artery disease - Results of NHIBI Type II coronary intervention study. Circulation 69: 325-337.
298. Berglund, U. and Wallentin, L. 1986. Influence on lipoprotein metabolism of platelet inhibitory drug ticlopidine. Atherosclerosis 59: 241-246.
299. Humphries, R. G., Tomlinson, W., Clegg, J. A., Ingall, A. H., Kindon, N. D., and Leff, P. 1995. Pharmacological profile of the novel P2T-purinoreceptor antagonist, FPL 67085 in vitro and in anesthesized rats in vivo. Br. J. Pharmacol. 115: 1110-1116.
300. Humphries, R. G., Robertson, M. J., and Leff, P. 1995. A novel series of P2T purinoreceptor antagonists: definition of the role of ADP in arterial thrombosis. Trends Pharmacol. Sci. 16: 179-181.
301. Humphries, R. G., Tomlinson, W., Ingall, A. H., Cage, P. A., and Leff, P. 1994. FPL 66096: a novel, highly potent and selective antagonist at human P2T purinoreceptor. Br. J. Pharmacol. 113: 1057-63.
302. 4A Hoppe Seyler's Z. Physiol. Chem. 365: 610-611.
303. Louie, S., Kim, B. K., and Zamecnik, P. C. 1988. Diadenosine 5′,5‴-P1,P4-tetraphosphate, a potential antithrombotic agent. Thromb. Res. 49: 557-566.
304. Proctor, R. A., Denlinger, L. C., Leventhal, P. S., Daugherty, S. K., Van De Loo, J.-W., Tanke, T., Firestein, G. S., and Bertics, P. J. 1994. Protection of mice from endotoxic death by 2-methylthio-ATP. Proc. Natl. Acad. Sci. U.S.A. 91: 6017-6020.
305. Seiss, W. 1989. Molecular mechanisms of platelet activation. Physiol. Rev. 69: 58-178.
306. Gachet, C. and Cazenave, J.-P. 1991. ADP-induced blood platelet activation: a review. Nouv. Rev. Franc. Hematol. 33: 347-358.
307. Hourani, S. M. O. and Hall, D. A. 1994. Receptors for ADP on human blood platelets. Trends Pharmacol. Sci. 15: 103-108.
308. MacKenzie, A. B., Mahaut-Smith, M. P., and Sage, S. O. 1996. Activation of receptor-operated cation channel via P2X1 not P2T purinoreceptors in human platelets. J. Biol. Chem. 271: 2879-2881.
309. McFarlane, D. E. 1987. Platelet responses and metabolism (Holmsen, H., Ed.), pp. 19-36, CRC Press, Boca Raton, FL.